Musaffa Logo
Hyperion DeFi Inc HYPD
$3.18 $0.04 (1.27%) 1D

Last Updated: Aug 21, 12:00 AM·NASDAQ

Pricing for US stocks is delayed by 24 hours

HYPD Shariah Compliance

Screening Methodology: AAOIFI

As of August 2026, Hyperion DeFi Inc is classified as doubtful.

DOUBTFUL

Report Source: undefined Quarter Report

Hyperion DeFi Inc

Hyperion DeFi Inc. Stock Analysis HYPD

United States Health Care Nano Cap

Hyperion DeFi Inc (HYPD) Chart

Financial Metrics & Statements of Hyperion DeFi Inc (HYPD)

FAQ's for Hyperion DeFi Inc (HYPD)

  • As of August 2026, Hyperion DeFi Inc HYPD is classified as doubtful according to Musaffa’s Shariah screening methodology. This classification is based on an assessment of the company’s business activities and financial ratios against Islamic investment guidelines.
  • A stock is Shariah-compliant if the company operates in permissible business activities and meets Islamic financial screening thresholds. Musaffa analyzes Hyperion DeFi Inc using these criteria to determine its compliance status.
  • Muslim investors may consider investing in Hyperion DeFi Inc if it meets Shariah compliance standards. Investors typically review the company’s business activities, debt levels, and non-permissible income before making a decision.
  • Musaffa determines the Shariah status of Hyperion DeFi Inc by analyzing whether the company’s core business operations are permissible and whether its financial ratios fall within accepted Islamic thresholds.
  • The Shariah compliance status of Hyperion DeFi Inc may be updated periodically when new financial statements, earnings reports, or business activity information become available.
  • Yes. A stock that is currently Shariah-compliant may become non-compliant if the company’s financial ratios exceed Shariah thresholds or its business activities change.
  • You can check the latest Shariah compliance status of Hyperion DeFi Inc on Musaffa’s stock page, where screening results and key financial indicators are updated to help Muslim investors make informed decisions.